BACKGROUND: Airway mucus hypersecretion is a key pathophysiologic feature in a number of lung diseases. Cigarette smoke/nicotine and allergens are strong stimulators of airway mucus; however, the mechanism of mucus modulation is unclear. OBJECTIVES: We sought to characterize the pathway by which cigarette smoke/nicotine regulates airway mucus and identify agents that decrease airway mucus. METHODS: IL-13 and γ-aminobutyric acid type A receptors (GABA(A)Rs) are implicated in airway mucus. We examined the role of IL-13 and GABA(A)Rs in nicotine-induced mucus formation in normal human bronchial epithelial (NHBE) and A549 cells and secondhand cigarette smoke-induced, ovalbumin-induced, or both mucus formation in vivo. RESULTS: Nicotine promotes mucus formation in NHBE cells; however, the nicotine-induced mucus formation is independent of IL-13 but sensitive to the GABA(A)R antagonist picrotoxin. Airway epithelial cells express α7-, α9-, and α10-nicotinic acetylcholine receptors (nAChRs), and specific inhibition or knockdown of α7- but not α9/α10-nAChRs abrogates mucus formation in response to nicotine and IL-13. Moreover, addition of acetylcholine or inhibition of its degradation increases mucus in NHBE cells. Nicotinic but not muscarinic receptor antagonists block allergen- or nicotine/cigarette smoke-induced airway mucus formation in NHBE cells, murine airways, or both. CONCLUSIONS: Nicotine-induced airway mucus formation is independent of IL-13, and α7-nAChRs are critical in airway mucous cell metaplasia/hyperplasia and mucus production in response to various promucoid agents, including IL-13. In the absence of nicotine, acetylcholine might be the biological ligand for α7-nAChRs to trigger airway mucus formation. α7-nAChRs are downstream of IL-13 but upstream of GABA(A)Rα2 in the MUC5AC pathway. Acetylcholine and α7-nAChRs might serve as therapeutic targets to control airway mucus.
BACKGROUND: Airway mucus hypersecretion is a key pathophysiologic feature in a number of lung diseases. Cigarette smoke/nicotine and allergens are strong stimulators of airway mucus; however, the mechanism of mucus modulation is unclear. OBJECTIVES: We sought to characterize the pathway by which cigarette smoke/nicotine regulates airway mucus and identify agents that decrease airway mucus. METHODS:IL-13 and γ-aminobutyric acid type A receptors (GABA(A)Rs) are implicated in airway mucus. We examined the role of IL-13 and GABA(A)Rs in nicotine-induced mucus formation in normal human bronchial epithelial (NHBE) and A549 cells and secondhand cigarette smoke-induced, ovalbumin-induced, or both mucus formation in vivo. RESULTS:Nicotine promotes mucus formation in NHBE cells; however, the nicotine-induced mucus formation is independent of IL-13 but sensitive to the GABA(A)R antagonist picrotoxin. Airway epithelial cells express α7-, α9-, and α10-nicotinic acetylcholine receptors (nAChRs), and specific inhibition or knockdown of α7- but not α9/α10-nAChRs abrogates mucus formation in response to nicotine and IL-13. Moreover, addition of acetylcholine or inhibition of its degradation increases mucus in NHBE cells. Nicotinic but not muscarinic receptor antagonists block allergen- or nicotine/cigarette smoke-induced airway mucus formation in NHBE cells, murine airways, or both. CONCLUSIONS:Nicotine-induced airway mucus formation is independent of IL-13, and α7-nAChRs are critical in airway mucous cell metaplasia/hyperplasia and mucus production in response to various promucoid agents, including IL-13. In the absence of nicotine, acetylcholine might be the biological ligand for α7-nAChRs to trigger airway mucus formation. α7-nAChRs are downstream of IL-13 but upstream of GABA(A)Rα2 in the MUC5AC pathway. Acetylcholine and α7-nAChRs might serve as therapeutic targets to control airway mucus.
Authors: Frédéric Sgard; Eric Charpantier; Sonia Bertrand; Nancy Walker; Daniel Caput; David Graham; Daniel Bertrand; François Besnard Journal: Mol Pharmacol Date: 2002-01 Impact factor: 4.436
Authors: Douglas A Kuperman; Xiaozhu Huang; Laura L Koth; Grace H Chang; Gregory M Dolganov; Zhou Zhu; Jack A Elias; Dean Sheppard; David J Erle Journal: Nat Med Date: 2002-07-01 Impact factor: 53.440
Authors: Gloria S Forkuo; Amanda N Nieman; Revathi Kodali; Nicolas M Zahn; Guanguan Li; M S Rashid Roni; Michael Rajesh Stephen; Ted W Harris; Rajwana Jahan; Margaret L Guthrie; Olivia B Yu; Janet L Fisher; Gene T Yocum; Charles W Emala; Douglas A Steeber; Douglas C Stafford; James M Cook; Leggy A Arnold Journal: Mol Pharm Date: 2018-04-02 Impact factor: 4.939
Authors: Rajwana Jahan; Michael Rajesh Stephen; Gloria S Forkuo; Revathi Kodali; Margaret L Guthrie; Amanda N Nieman; Nina Y Yuan; Nicolas M Zahn; Michael M Poe; Guanguan Li; Olivia B Yu; Gene T Yocum; Charles W Emala; Douglas C Stafford; James M Cook; Leggy A Arnold Journal: Eur J Med Chem Date: 2016-11-24 Impact factor: 6.514
Authors: Yael-Natalie H Escobar; Cameron B Morrison; Yuzhi Chen; Elise Hickman; Charlotte A Love; Meghan E Rebuli; Jason D Surratt; Camille Ehre; Ilona Jaspers Journal: Am J Physiol Lung Cell Mol Physiol Date: 2021-04-07 Impact factor: 6.011
Authors: Elena Y Enioutina; Elizabeth J Myers; Petr Tvrdik; John R Hoidal; Scott W Rogers; Lorise C Gahring Journal: PLoS One Date: 2015-03-24 Impact factor: 3.240
Authors: Sravanthi Gundavarapu; Neerad C Mishra; Shashi P Singh; Raymond J Langley; Ali Imran Saeed; Carol A Feghali-Bostwick; J Michael McIntosh; Julie Hutt; Ramakrishna Hegde; Shilpa Buch; Mohan L Sopori Journal: PLoS One Date: 2013-10-14 Impact factor: 3.240